Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 393

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 393
---
 or through issuance of Company securities, as to be agreed upon by the parties. The Pluri Agreement further provides that after completion of first phase, subsequent phases of work may be initiated only upon written agreement of both parties, subject to capacity availability at Pluri’s facilities. Pricing for subsequent phases will be negotiated separately and is valid for 12months from June30, 2024. Kadimastem is responsible for providing all process and assay data, starting materials, and raw materials unless otherwise agreed, and may be charged a 15% handling fee on raw materials procured by Pluri. Kadimastem retains ownership of all materials and intellectual property provided under the Pluri Agreement, and grants Pluri a limited right to use such knowledge solely for the purpose of performing the services. The Pluri Agreement may be terminated: (i) by either party upon a material breach not cured within 30 days of notice; (ii) immediately by either party if the other becomes insolvent or subject to certain bankruptcy events; or (iii) by Kadimastem, without cause, upon 30 days’ written notice after the first 90 days of the agreement. In the event of termination, Kadimastem must pay for services rendered and non -cancellablecosts incurred up to the termination date. As of the date of this proxy statement/prospectus, $28,300 have been paid by Kadimastem to Pluri under this agreement. Intellectual Property Kadimastem seeks and has obtained some patent protection as well as other effective intellectual property rights for Kadimastem’s products and technologies in the United States and internationally. Kadimastem’s policy is to pursue, maintain and defend intellectual property rights developed internally and to protect the technology, inventions and improvements that are commercially important to the development of its business. A list of each of Kadimastem’s patent families, including each of their status, their filing locations, and application information, is set forth below:

| METHODS OF GENERATING GLIAL AND NEURONAL CELLS |     |           |     |            |     |                   |     |             |     |                    |     |                                                                                        |     |         |     |                                                                                                             |     |                 |
| Kadimastem Ref                                 
 Client Ref                                     |     | Country   |     | Earliest   
 Priority   |     | Entry Date        |     | Filing      
 Date        
 Application 
 No.         |     | Publication        
 Date + No.         
 Issue              
 Date +